A Multi-center Clinical Study of Fully Human BCMA Chimeric Antigen Receptor Autologous T (CAR-T) Cell Injection (CT103A) in the Treatment of Newly Diagnosed Subjects With High-risk Multiple Myeloma (FUMANBA-2)
Latest Information Update: 16 Sep 2024
At a glance
- Drugs Equecabtagene autoleucel (Primary)
- Indications Multiple myeloma
- Focus Therapeutic Use
- Acronyms FUMANBA-2
- Sponsors Nanjing IASO Biotherapeutics
Most Recent Events
- 15 Jun 2024 According to a Nanjing IASO Biotherapeutics media release, as of January 25th, 2024, 16 subjects received Eque-cel therapy.
- 15 Jun 2024 Results presented in the Nanjing IASO Biotherapeutics Media Release.
- 15 Jun 2024 According to a Nanjing IASO Biotherapeutics media release, results from this trial were presented at the 2024 European Hematology Association (EHA) Annual Congress.